Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Cipla
Fish and Richardson
QuintilesIMS
Moodys
Covington
Citi
Farmers Insurance
Healthtrust

Generated: October 17, 2017

DrugPatentWatch Database Preview

ZANTAC 150 Drug Profile

« Back to Dashboard

What is the patent landscape for Zantac 150, and when can generic versions of Zantac 150 launch?

Zantac 150 is a drug marketed by Glaxo Grp Ltd, Glaxosmithkline, and Sanofi Us. and is included in four NDAs.

The generic ingredient in ZANTAC 150 is ranitidine hydrochloride. There are forty-three drug master file entries for this compound. One hundred and forty-three suppliers are listed for this compound. Additional details are available on the ranitidine hydrochloride profile page.

Summary for Tradename: ZANTAC 150

US Patents:0
Applicants:3
NDAs:4
Suppliers / Packagers: see list5
Bulk Api Vendors: see list72
Clinical Trials: see list2,207
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ZANTAC 150 at DailyMed

Pharmacology for Tradename: ZANTAC 150

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxo Grp Ltd
ZANTAC 150
ranitidine hydrochloride
TABLET;ORAL018703-001Jun 9, 1983ABRXYesNo► Subscribe► Subscribe► Subscribe
Glaxosmithkline
ZANTAC 150
ranitidine hydrochloride
CAPSULE;ORAL020095-001Mar 8, 1994DISCNYesNo► Subscribe► Subscribe► Subscribe
Glaxo Grp Ltd
ZANTAC 150
ranitidine hydrochloride
GRANULE, EFFERVESCENT;ORAL020251-002Mar 31, 1994DISCNNoNo► Subscribe► Subscribe► Subscribe
Glaxo Grp Ltd
ZANTAC 150
ranitidine hydrochloride
TABLET, EFFERVESCENT;ORAL020251-001Mar 31, 1994DISCNNoNo► Subscribe► Subscribe► Subscribe
Sanofi Us
ZANTAC 150
ranitidine hydrochloride
TABLET;ORAL021698-002Mar 13, 2007OTCYesNo► Subscribe► Subscribe► Subscribe
Sanofi Us
ZANTAC 150
ranitidine hydrochloride
TABLET;ORAL021698-001Aug 31, 2004OTCYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ZANTAC 150

Paragraph IV (Patent) Challenges for ZANTAC 150

Drugname Dosage Strength RLD Submissiondate
ranitidine hydrochlorideTablets150 mgZantac 15010/30/2007
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Daiichi Sankyo
Fish and Richardson
Cantor Fitzgerald
Deloitte
Fuji
Chinese Patent Office
Express Scripts
Queensland Health
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot